MGMT and neoplasm: Moreover, MGMT is likely amenable to tumor-selective modulation in solid tumors increasing their preferential sensitivity towards chloroethylating BSHs [6,14], and the presence of MGMT deficient tumors in 5–20% of patients (dependent upon the tumor type) may permit the pre-selection of patients likely to exhibit exceptional responses [15,16,17].